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Mycobacterium tuberculosis (MTB) is an airborne pathogen that is easily transmitted from 
person to person. An intact immune system prevents the organism from causing disease in 
most individuals. In South Africa, the prevalence of human immunodeficiency virus (HIV) 
has reached astronomical levels and is now fuelling the tuberculosis (TB) epidemic. Drug 
resistant MTB strains combined with a weakened host immune system is a lethal 
combination. Multi-drug resistant (MDR) including extensively drug resistant (XDR) 
tuberculosis is on the increase, with Tugela Ferry in KwaZulu-Natal South Africa, 
reporting the largest cluster of XDR cases in the world. It is unknown whether a single 
clone of the drug resistant strain is circulating in this area or whether there are multiple 
strains at play. Using 2 complementary genotyping methods, we showed that the MDR 
strains present are the result of clonal spread associated with the F28 family, as well as de 
novo resistance which manifests as unique patterns. The XDR epidemic in Tugela Ferry is 
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Tuberculosis (TB) continues to be a major cause of human morbidity and mortality in the 
developing world (Ahmed et al., 2011; Rodriguez et al., 2010). Human immunodeficiency 
virus (HIV) associated immune suppression increases susceptibility to co-infection with 
Mycobacterium tuberculosis (MTB). The KwaZulu-Natal (KZN) Province in South Africa 
is the epicenter of the global HIV epidemic (KZN LED Report, 2005; York et al., 2000). 
TB in this province is fuelled by the increasing number of immune-suppressed individuals. 
 
In 2005 a cluster of 53 HIV-infected patients with extensively drug-resistant tuberculosis 
(XDR-TB) was detected in, the catchment area for the Church of Scotland Hospital 
(CoSH) in Tugela Ferry, in the KZN province, South Africa. Tugela Ferry is a rural town 
that is inhabited by approximately 300 000 Zulu people. This ‗outbreak‘  caused global 
alarm since this was not only the largest reported cluster of patients with XDR TB, but the 
majority of patients had demised before the drug susceptibility testing (DST) results 
became available (Gandhi et al., 2006). 
 
In March 2006 XDR TB was reported to have a worldwide distribution, and was deemed a 
potential global threat by the Centers for Disease Control and Prevention (CDC) (CDC 
MMWR, 2006). Between November 2004 and November 2005, the World Health 
Organization (WHO) and CDC conducted a survey by obtaining data from an international 
network of TB laboratories. The supranational TB laboratory reference network consisted 
of 25 reference laboratories, on six continents. A total of 17690 TB isolates from the 
period 2000-2004 were tested for susceptibility to three second line drugs. The results 
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revealed that of the 17690 TB isolates 20% (3520/17690) were multidrug resistant 
tuberculosis (MDR-TB) and 2% (347/17690) were XDR TB. Of the 3520 MDR TB 
isolates, 1298 were from South Korea of which 15% (200/1298) were XDR TB. The 
remaining laboratories reported a combined total of 2222 MDR cases of which 7% 
(147/222) were XDR TB. Population based data on MTB drug susceptibility were obtained 
from United States of America (USA) for the period 1993-2000, Latvia 2000-2002 and 
South Korea 2004. Data from USA during 1993-2000 reported on a total of 169654 
patients, of which 1.6% were MDR TB cases. Of the MDR cases, 4.1% were XDR TB 
cases. In Latvia, of the 605 MDR TB cases who initiated therapy during 2000-2002, 19% 
were XDR TB cases. The proportion of XDR TB in these regions increased over the years 
2000-2004 (CDC MMWR, 2006).    
 
Of the XDR TB patients who sought treatment at the CoSH for their current TB illness, 30 
of the 53 were detected in the outpatient department. Fourteen of these gave no previous 
history of hospitalisation. There was no history of previous TB treatment in 55% of the 
XDR TB cases. This was the first indication that the Tugela Ferry ―outbreak‖ was not an 
isolated nosocomial outbreak at CoSH. All 44 patients tested for HIV were found to be 
positive. An analysis of the isolates using IS6110 restriction fragment length 
polymorphism (RFLP) and spoligotyping revealed that 85% (39/46 tested) patients were 
infected with a genetically similar XDR strain of MTB which belonged to the KZN family.  
The 7 other isolates were genotyped subsequent to publication and were also classified as 
belonging to the KZN family. This implied that possible transmission of the XDR TB 
strains may have occurred in the community, during clinic visits and/or on admission to the 
hospital wards (Gandhi et al., 2006; Dorman and Chaisson, 2007). 
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The aim of this study was to therefore genotype a selection of TB isolates from patients in 
the Tugela Ferry area to ascertain the genetic relatedness of locally circulating strains. This 
was accomplished by evaluating and comparing the usefulness of IS6110 RFLP and 



























2.1 Tuberculosis (TB) 
 
2.1.1 Epidemiology 
Approximately one third of the world‘s population is infected with TB (WHO, 2005). 
Every year, approximately 3 million deaths and 8 million new active cases occur. The 
global estimates of TB in 2009 were 9.4 million new cases with 1.7 million deaths which 
equated to 4700 deaths per day. Among the estimated 9.4 million new cases reported 3.3% 
had MDR TB. A recent WHO survey reported that the former Soviet Union with 28% had 
the highest incidence of MDR TB. XDR TB cases were confirmed in 58 countries (WHO, 
2010a; 2010b). 
 
South Africa ranks fourth on the WHO list of high TB burden countries (Schmidt, 2008; 
WHO, 2008). Since 1998 TB incidence in South Africa has increased. In KZN the number 
of TB cases reported in 1998 was 28637, this increased over the years to 39586 cases 
reported in 2001 (DOH TB Fact Sheet, 2003). In 2006 the incidence of TB in KZN was 
780 per 100 000 population (DOH, 2007). 
 
2.1.2 HIV co-infection 
Approximately 40 million people are infected with HIV worldwide and about one third are 
co-infected with TB. The majority of HIV-TB co-infected cases occur in sub Saharan 
Africa (WHO, 2005). In 2009 the global estimate of new HIV-TB co-infected cases, was 
1.1 million with 380 000 deaths (WHO, 2010a; 2010b). Tuberculosis is known as the 
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leading cause of death among HIV infected individuals. The dual epidemics of HIV and 
TB pose a major public health problem in South Africa. Whilst South Africa constitutes 
0.7% of the world‘s population, it contributed to 17% of the global burden of HIV 
infection in 2007 (Abdool Karim et al., 2009; Bimbaum et al., 2011; DOH, 2007). In 
South Africa between 60% and 80% of new TB cases occur in people who are co-infected 
with HIV (Mattheyse, 2007; Weyer, 2007). 
 
2.1.3 Physical characteristics of Mycobacterium tuberculosis 
Tuberculosis is caused by the organism Mycobacterium tuberculosis. MTB belongs to the 
order Actinomycetales, family Mycobacteriacea, and genus Mycobacterium 
(Encyclopaedia of Infectious Diseases, 2007). It is an acid fast bacillus, classified as an 
obligate aerobe. The organism is non-encapsulated, curved, beaded, rod-shaped and non- 
spore forming, measuring approximately 0.5µm in width and 3µm in length. It has a 
unique cell wall structure that contains fatty acids and mycolic acids which are covalently 
attached by the interwoven polysaccharide arabinogalactan to an underlying peptidoglycan 
layer (Knechel, 2009). 
 
2.1.4 Transmission 
Transmission of MTB occurs via the airborne or droplet routes (Mathema et al., 2006; 
Knechel, 2009). It is therefore easily spread from person to person especially in 
overcrowded and poorly ventilated environments such as prisons, clinics and hospitals. 
Higher incidence rates of TB are usually found in such environments as compared to the 
general population (Haugen, 2007). Nosocomial transmission is enhanced by inadequate 
triage and infection control practices (Basu et al., 2007). Increased poverty with poor 
access to medical care especially in rural and poorly resourced areas also influences 
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transmission of MTB (Haugen, 2007; Murphy, 2008). Overcrowding associated with 
poverty potentiates the transmission of TB. Higher rates of TB amongst immigrants have 
been linked to poverty. The movement of populations due to natural disasters with it 
ensuing crowding and malnutrition have also been associated with TB transmission 
(Glynn, 1998; Lienhardt, 2001). Factors affecting access to medical care is multifactorial 
and delays in access results in delayed diagnosis and treatment of TB, thus increasing the 
risk of transmission of TB in the community (CDC MMWR, 2005; Lienhardt, 2001). In 
KZN over 80 % of reported cases of tuberculosis are not culture-confirmed in keeping with 
the policy on diagnosis of tuberculosis in South Africa. Consequently, drug susceptibility 
testing is not done. This raises major concern since a significant proportion of patients with 
MDR/XDR TB are likely to die before it is realised that drug susceptibility tests are needed 
to guide their treatment. A recent study reported that more than 65 % of MDR, (including 
XDR) cases of culture-confirmed tuberculosis did not reach the referral centre in KZN and 
therefore remained untreated. The disease in these patients was therefore inappropriately 
managed and they represent a pool of potential transmitters of drug-resistant tuberculosis, 
both in the community and institutional settings (Moodley et al., 2011).  
 
2.2 Genotyping of Mycobacterium tuberculosis 
 
2.2.1 Genome characteristics 
The genome of MTB has approximately 4.4 mega base-pairs (bps) and contains 3924 open 
reading frames (Cole et al., 1998). Although mobile insertion sequences (IS) and 
polymorphic regions are found, the genome remains highly conserved (Mathema et al., 
2008). Many genetic markers within the MTB genome have been identified. However, 
only a few offer sufficient discrimination and reliable reproducibility (Kremer et al., 1999). 
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Eisenach et al. (1988) and Zainuddin and Dale (1989) recognised the existence of 
repetitive deoxyribonucleic acid (DNA) elements in the organism and its potential 
contribution to strain typing of MTB. The IS6110 element was first reported by Thierry et 
al. (1990a, 1990b). IS6110 is a member of the IS3 family (Otal et al., 1991; Thierry et al., 
1990a; Thierry et al., 1990b). It is a small mobile genetic element which encodes its own 
transposase but does not encode a phenotypic marker (Mathema et al., 2006). It comprises 
1355bps and contains an imperfect 28bp inverted repeat at the ends (Thierry et al., 1990a; 
Thierry et al., 1990b). The IS6110 is present in different copy numbers and integrated at 
various regions within the MTB genome (Mathema et al., 2006). The gold standard for 
MTB genotyping is restriction fragment length polymorphism (RFLP) using IS6110 as a 
genetic marker (Van Embden et al., 1993). 
 
Another extensively studied region within the MTB genome is the polymorphic direct 
repeat region (DR) which is the basis for another MTB genotyping method viz: 
spoligotyping. The DR region has a unique structure as it contains directly repeated 
sequences interspersed with unique sequences. The DR region is 36bps and the 
interspersed sequences range from 34 to 41bps (Hermans et al., 1991; Kamerbeek et al., 
1997; van Embden et al., 2000; Warren et al., 2002). The spoligotyping technique was 
developed and is used as an epidemiological tool which targets the DR regions 
(Kamerbeek et al., 1997; Streicher et al., 2007). 
 
2.2.2 Genotyping methods available for Mycobacterium tuberculosis 
Key factors in controlling spread of TB include rapid detection, adequate treatment and 
contact tracing to stop further transmission. Genotyping of MTB facilitates identification 
of disease transmission routes, differentiation of re-infection from reactivation and 
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detection of laboratory cross contamination. IS6110 RFLP and spoligotyping are the most 
frequently used techniques. 
 
2.2.2.1 Roles of genotyping methods 
IS6110 RFLP is well suited to study molecular epidemiology of MTB strains and can also 
be used for evolutionary and phylogeny studies (Mathema et al., 2006). Using 
spoligotyping more conserved genetic information is visualised and this method can be 
used to classify MTB complex into taxons and subspecies (Van Soolingen, 2001). 
MIRU:VNTR is also well adapted to study molecular epidemiology of MTB strains.  It has 
the potential for real time genotyping and high throughput typing. Single nucleotide 
polymorphism (SNP) based genotyping is considerably more powerful for examining the 
population based structure of MTB. It is also used for phylogenetic classification of strains 
(Mathema et al., 2006).   
 
2.2.2.2 IS6110 Restriction Fragment Length Polymorphism (RFLP) 
IS6110 RFLP remains the gold standard, which targets the IS6110 transposable element 
located in the MTB genome (Van Embden et al., 1993). RFLP is useful for detecting 
outbreaks and conducting population based studies of recent transmission. 
Epidemiologically unrelated strains of TB can be distinguished by different fingerprint 
patterns whilst linked strains have identical patterns (Barnes and Cave, 2003).   
 
Although IS6110 RFLP is highly reliable and remains the gold standard it also has many 
limitations. This genotyping technique is labour intensive and requires weeks of incubation 
to obtain sufficient amounts of DNA (DeRiemer and Daley, 2004; Kanduma et al., 2003). 
Isolates which have a low copy number of IS6110 insertions are insufficiently 
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discriminated since there is a limited degree of polymorphism. Hence supplementary 
methods of genotyping have to be used (Barnes and Cave, 2003; DeRiemer and Daley, 
2004; Kanduma et al., 2003; Mathema et al., 2006). Genetic variability of MTB exists 
worldwide and IS6110 RFLP alone cannot distinguish among strains with too low or too 
high copy numbers of insertion sequences since poorly informative or complex patterns are 
generated. Alternative genotyping methods have been developed to circumvent these 
problems (Sola et al., 2003). 
 
2.2.2.3 Spoligotyping 
Spoligotyping is a polymerase chain reaction (PCR) based technique which is simple, 
robust and highly reproducible. It targets spacer sequences which are present between 
repetitive segments located in the direct repeat locus, by PCR and reverse dot-blot analysis 
(Kamerbeek et al., 1997). 
 
MTB strains differ by the presence or absence of spacers and patterns of spacers are used 
to analyse the genotype. Results generated are highly reproducible and binary data are 
easily interpreted, computerized and amendable to inter-laboratory comparisons. 
Spoligotyping requires small amounts of DNA and can also be performed on isolates of 
MTB shortly after a clinical specimen has been inoculated into liquid culture (Barnes and 
Cave, 2003; DeRiemer and Daley, 2004; Mathema et al., 2006). 
 
The discriminatory power is inferior as compared to IS6110 RFLP analysis (Kremer et al., 
1999; Mathema et al., 2006). Identical spoligotype patterns but differing IS6110 RFLP 
patterns are often encountered. In endemic areas transmission events are unable to be 
discerned but low copy number strains can be discriminated. Discriminatory power of 
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spoligotyping when used alone is limited since a single locus which accounts 0.1% of the 
MTB genome is being targeted (Kanduma et al., 2003; Kremer et al., 1999; Mathema et 
al., 2006). 
 
2.2.2.4 Polymorphic GC-rich repetitive sequences (PGRS) 
PGRS is a southern blot hybridization technique which utilizes a PGRS specific probe 
cloned in plasmid pTBN12. This technique is resource intensive and patterns generated are 
too complex to computerize for standardization and analysis (Mathema et al., 2006; Ross 
et al., 1992). 
 
2.2.2.5 Pulse Field Gel Electrophoresis (PFGE) 
PFGE is used to simplify IS6110 RFLP. It uses a less frequently cutting enzyme and 
produces high molecular weight fragments which are separated under special conditions. 
However, small polymorphism differences for different strains are observed and do not 
always produce sufficient discrimination (Kanduma et al., 2003).  
 
2.2.2.6 Mycobacterial interspersed repetitive units - Variable number-tandem repeat 
(MIRU-VNTR) Typing 
An alternative PCR based technique has recently been described called MIRU-VNTR 
which targets 12 to 24 loci containing, a variable number of tandem repeats of genetic 
elements named mycobacterial interspersed repetitive units. These are located mainly in 
intergenic regions interspersed in the MTB genome (Alonso-Rodriguez et al., 2008; 
Supply et al., 2006). The automation of the technique via ABI-gel based sequencing or 
Beckman capillary based sequencing has improved its rapidity and convenience. MIRU-
VNTR genotyping is simpler than IS6110 RFLP and can be applied directly to MTB 
11 
 
cultures without DNA purification. The data generated are highly amendable to inter and 
intra-laboratory comparisons. Analysis can be automated and used to evaluate a large 
number of strains. The discriminatory power of MIRU-VNTR analysis is proportional to 
the number of loci evaluated. When 12 loci are used MIRU-VNTR is less discriminate 
relative to IS6110 RFLP for isolates with a high IS6110 copy number and more 
discriminate for isolates with a low IS6110 copy number. When more than 12 loci are used 
or MIRU-VNTR and spoligotyping analysis are combined the discriminatory power 
approximates that of IS6110 RFLP analysis (Barnes and Cave, 2003; Marzars et al., 2001; 
Mathema et al., 2006; Supply et al., 2001). 
 
2.2.3 Genotyping and Drug Resistance 
MDR and XDR TB cases are the result of primary transmission of already resistant strains 
and/or de novo development of resistance within an individual. Primary MDR or XDR TB 
occurs via transmission of an already resistant strain and is by definition clonal because the 
same strain is responsible for two or more cases. In contrast, de novo acquisition of drug 
resistance occurs in a single patient during treatment by the outgrowth of minor 
populations of drug resistant organisms in a largely susceptible population under selective 
pressure of exposure to drug. MTB strains which develop de novo resistance are not related 
to clonal spread, but may contribute to strain diversity in an area. The spread of already 
resistant MTB strains in an area is often clonal and may be linked to an outbreak (Bifani et 
al., 1996; Edlin et al., 1992; Gandhi et al., 2006). Multiple drug resistant clusters have also 
been described in some areas implying that more than one outbreak occurred concurrently. 
MTB strains which acquire de novo resistance in an individual may be transmitted to 




The MDR and XDR susceptibility profiles of strains of MTB have been linked to certain 
families. Studies have shown that MDR strains were associated with the Beijing family 
(Almeida et al., 2005; Johnson et al., 2006; Mistry et al., 2002). In KZN, the 
F15/LAM4/KZN family were found to be dominant amongst the MDR and XDR isolates 
(Gandhi et al., 2006; Pillay and Sturm, 2007). A study by Mlambo et al., (2008) found a 
high diversity in the genotypes of XDR MTB strains from different geographical locations 
throughout South Africa.  These findings indicated that a significant number of the XDR 
TB cases were due to de novo acquisition of drug resistance rather than primary 
transmission.  XDR TB in South Africa is not in general due to the spread of a single 
outbreak strain but more often the result of de novo acquired resistance. Two different 
mechanisms of evolution of XDR TB may be operating in Tugela Ferry and the country as 
a whole is not a mutually exclusive hypotheses. 
 
Acquired drug resistance by the spontaneous insertion of IS6110 elements into genes 
associated with pyrazinamide activity has been reported (Lemaitre et al., 1999). A study by 
Purwar et al., (2011) attempted to define an association between drug resistance and 
IS6110 copy numbers. They reported that isolates with identical IS6110 copy numbers had 
different susceptibility profiles and vice versa. Although resistant strains have been 
associated with specific strain families, the relationship between specific patterns 
generated by genotyping analysis and susceptibility profiles remains unclear. 
 
2.3 Genotyping and Outbreaks of Mycobacterium tuberculosis 
Strains of W/Beijing strain family of MTB have been responsible for many large outbreaks 
in correctional institutes and nosocomial environments (Bifani et al., 2002; Glynn et al., 
2002). The Haarlem strain family has also been documented on different continents such as 
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Europe, Asia and Africa. The Haarlem strain family has been responsible for a few 
outbreaks which have been reported in Argentina, Czech Republic and Tunisia (Kubin et 
al., 1999; Mardassi et al., 2005; Ritacco et al., 1997). 
 
2.3.1 New York City  
In the early 1990‘s a multi-drug resistant MTB strain was identified in New York City. It 
was resistant to isoniazid, rifampin, ethambutol, streptomycin and in most instances 
kanamycin. Analysis of the strain revealed that it was a member of the Beijing strain 
family. This strain spread rapidly among a HIV positive population and 357 cases were 
reported from prisons and hospitals. DNA fingerprinting revealed that 253 of the cases 
shared an identical 18 banded pattern or similar IS6110 pattern and were therefore 
associated with clonal spread (Bifani et al., 1996; Bifani et al., 2002; Glynn et al., 2002). 
 
2.3.2 Argentina  
In Buenos Aires, during January 1994 – June 1995 an increase of MDR TB was identified 
at a referral treatment centre among HIV infected patients. A total of 124 HIV positive 
patients with MDR TB were identified of which 101 TB isolates had resistance to 5 drugs. 
IS6110 RFLP analysis was done on 77 isolates. Of the 77 patients 74 were hospitalised in 
the previous year. An additional 3 MDR TB isolates from HIV positive patients and 35 TB 
isolates of HIV negative patients, who were present in the hospital during 1992-1993 were 
also analysed. IS6110 RFLP analysis revealed that 68 of the 74 isolates from 1994-1995 
clustered and 2 of the 3 isolates from 1992 belonged to the M genotype. The IS6110 RFLP 
patterns resembled those of the Haarlem family. The strain involved in the outbreak was 
traced to HIV positive patients hospitalised in 1992. The clinical records of both patients 
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suggested nosocomial infection. It was likely that this strain or an ancestor had been 
brought into the hospital prior to the occurrence of an outbreak (Ritacco et al., 1997). 
 
2.3.3 Italy  
In Europe the largest nosocomial outbreak during October 1991- July 1995 occurred in 
Milan. The MTB strains were resistant to 4 first line drugs and were present among HIV 
positive patients in 2 large urban hospitals in Milan. A total of 116 MDR TB cases were 
identified among 2 urban hospitals. In one hospital, (A) 85 cases were identified and 31 
cases in a second hospital (B). A patient infected at hospital A had introduced the strain 
into hospital B. IS6110 RFLP analysis was done on 92 of the 116 MDR TB isolates and 82 
of these 92 isolates clustered in one genotype. The results revealed that nosocomial 
transmission occurred in hospital A among 39 of the 56 patients and 24 of the 26 in 
hospital B. For 8 patients with the outbreak strain, exposure was reported to have occurred 
in other hospitals, in the community or in prison. IS6110 RFLP patterns in this study 
differed from the commonly found Beijing strain associated with numerous outbreaks 
(Moro et al., 1998). 
 
2.3.4 Iran  
The existence and transmission of XDR TB among MDR TB patients was evaluated in 
Iran among patients that were referred for treatment and diagnosis during 2003-2005. A 
total of 12 XDR TB isolates were identified among 113 MDR TB isolates. Spoligotyping 
and IS6110 RFLP analysis were performed on the XDR TB isolates. Retrospective 
analysis revealed that 2 clusters were present. In cluster I, 8 isolates were present and these 
isolates were reported as being involved in an outbreak among a family and community 
members associated with this family. The first patient had infected 2 of the siblings and 5 
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other patients who had shared a room with this patient. In cluster II, the outbreak strain was 
found among 4 family members. Spoligotyping and IS6110 RFLP results revealed that the 
MTB strains belonged to the Haarlem 1 and the East African Indian (EAI) 3 families of 
strains (Masjedi et al., 2006). 
 
2.4 Genotyping and Prevalent Mycobacterium tuberculosis strains 
 
2.4.1 China  
The Beijing family of MTB strains are described as endemic in China and dominant in 
neighbouring countries of Mongolia, South Korea and Thailand, while relatively low in 
prevalence but emerging on other continents.  While drug resistance has been associated 
with Beijing strains in other parts of the world, including New York, Cuba, Estonia and 
Vietnam, these strains have not been significantly associated with drug resistance in other 
countries. In China the Beijing family of strains are the most prevalent MTB strains 
circulating in the population, indicative of a long history of endemicity. Drug resistant 
Beijing strains are relatively uncommon in this part of the world. The Beijing MTB strain 
possesses similar molecular epidemiological characteristics to those MTB strains reported 
during the New York City outbreak (Bifani et al., 2002; Glynn et al., 2002; Van Soolingen 
et al., 1995). 
 
2.4.2 Mozambique  
A study conducted in Mozambique by Viegas et al. (2010) analysed 445 MTB isolates 
using spoligotyping. The four predominant genotypes which were identified included the 
Latin-American Mediterranean (LAM) lineage which accounted for 37%, the East African-
Indian (EAI) which accounted for 29.7%, the T lineage which accounted for 11.6% and the 
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Beijing lineage which accounted for 7%. A great diversity of spoligotyping patterns was 
found within the LAM, EAI and T lineages. The spread of MTB in Mozambique is 
facilitated by various circulating strains with different spoligotype patterns and 4 
predominant lineages (Brudey et al., 2006; Viegas et al., 2010). 
 
2.4.3 Zambia  
In a study conducted by Chihota et al. (2007), MTB isolates from Zambia were analysed 
by spoligotyping. The results revealed that 63.2% of the isolates had a characteristic 
spoligotype pattern. The results also showed that 6 isolates shared a spoligotype pattern 
with isolates from Zimbabwe and 4 isolates shared a spoligotype pattern with isolates from 
Cape Town. 
 
In a study done by Mulenga et al. (2010) in the Ndola district of Zambia 273 MTB isolates 
were genotyped using spoligotyping to establish the different lineages of MTB circulating 
in this area. Of the 273 isolates 177 isolates belonged to a lineage present in the 
international SpolDB4 database and 96 isolates did not match any of the spoligotype 
patterns present on the SpolDB4 database. These isolates were referred to as orphans. The 
predominant spoligotype family was the LAM lineage. The majority of the isolates in the 
LAM lineage belonged to the LAM11-ZWE sub-lineage which is designated as the 
Southern Africa Family 1 (SAF1). Other lineages which were common among the isolates 
included the T lineage and X lineage. A small proportion of the isolates also belonged to 






2.4.4 Zimbabwe  
In a study done by Chihota et al. (2007) the genetic diversity of MTB isolates were 
analysed using spoligotyping and IS6110 RFLP. Isolates were obtained from patients 
presenting to referral hospitals in Zimbabwe. A predominant group was identified among 
the isolates which had a characteristic IS6110 banding pattern and a unique spoligotype 
signature which had spacers 21-24, 27-30 and 33-36 absent. This indicated a clonal 
expansion from a common progenitor. This group of strains were designated the Southern 
Africa family 1 (SAF1). Previous studies have shown that SAF1 is a member of the LAM 
lineage (Brudey et al., 2006). Comparison between the IS6110 RFLP patterns among the 
Zimbabwean isolates and IS6110 RFLP patterns of Cape Town isolates on a database 
showed a close relation to a strain family in Cape Town with 2.3% of Cape Town TB 
isolates related. Four IS6110 RFLP patterns and 3 spoligotype patterns were shared 
between Zimbabwe and Cape Town. Among the Cape Town isolates 8 had the 
characteristic SAF1 spoliogtype signature. The unique and predominant SIT59 pattern was 
compared to the SpolDB3 database. This pattern was found to be rare in other parts of the 
world but common in Southern Africa (Chihota et al., 2007).  
 
2.4.5 Botswana  
In a study by Lockman et al. (2001) patterns of TB transmission were analysed using 
IS6110 RFLP. MTB isolates were obtained from patients from four communities in 
Botswana during January 1997-June 1998. IS6110 RFLP patterns which had >5 bands 
were considered to be clustered if they had identical patterns or differed by 1 band. 
Patterns which had ≤5 bands were considered clustered if all bands were identical. Of the 




2.4.6 South Africa  
In South Africa different families of strains have been described in different areas of the 
country. 
 
2.4.6.1 Western Cape strains 
In the Western Cape in South Africa in 2004 over 44000 people had been diagnosed with 
TB of whom 450-600 had MDR TB (Johnson et al., 2006). MDR TB was 1
st
 identified in 
1985 in the Western Cape (Streicher et al., 2004). The TB epidemic in the Western Cape 
Province is primarily driven by four MTB strains. These strains include the Beijing strain 
which predominates among those responsible for drug resistance. An outbreak with a 
specific cluster of the Beijing strain occurred in Cape Town in 2005. Analysis of isolates of 
4 school children identified with MDR TB revealed that the cluster contained a specific 
mutation in the inhA gene conferring isoniazid resistance. These isolates belonged to the 
Beijing cluster 220. Archived MTB drug resistant strains were also analysed and 28% 
belonged to the Beijing cluster 220 and an additional 42% had a mutation in the rpoB 
gene. The presence of these transmissible MDR TB strains poses a threat to the community 
(Johnson et al., 2006). 
 
The F11 and F28 genotypes are also present in the Western Cape. The F11 genotype has 
been identified as the most successful strain in this province and is also present on four 
other continents and in 25 different countries. The F11 genotype can be identified by a 
unique spoligotype pattern and dot blot screening for a specific rrs491 polymorphism 
(Streicher et al., 2004; Victor et al., 2004). The DRF 150 genotype was detected during an 
outbreak of an emerging resistant non-Beijing strain. This genotype is identified by 5 
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IS6110 insertions, a specific spoligotype and high levels of resistance to isoniazid, 
rifampicin and streptomycin (Victor et al., 2007). 
 
2.4.6.2 KwaZulu-Natal 
In a study by Pillay and Sturm (2007) the strain that was found in KZN was classified as 
belonging to the F15/LAM4/KZN family. The F15 family forms part of the Latino-
American and Mediterranean family and corresponds with the LAM4 sub-lineage 
(Streicher et al., 2007). These strains were found to have a spoligotype pattern which had 
been reported previously (Brudey et al., 2006; Filliol et al., 2003). The pattern was known 
to have spacers 21-24, 33-36 and 40 absent but the IS6110 RFLP fingerprint pattern was 
found to be unique. The F15/LAM4/KZN family strain has been present in KZN as early 
as 1994 and has been associated with many MDR TB cases which had been genotyped 
during 1994-2002. In 2001 the first XDR TB isolate was identified in one patient and 
possessed the F15/LAM4/KZN fingerprint pattern (Pillay and Sturm, 2007). During 2005 
in Tugela Ferry isolates from the XDR TB cases also displayed the F15/LAM4/KZN 
fingerprint (Gandhi et al., 2006).   
 
During 1994-1997 a study in patients from the community in Durban revealed that the 
Beijing strain was predominant and all isolates were fully drug susceptible (Pillay and 
Sturm, 2010). 
 
2.5 Why Study The Molecular Epidemiology of Strains in KZN? 
KZN being a region with high endemicity of HIV has an increasing population of immune 
suppressed individuals. This compounds the ease with which MTB is transmitted in. 
Additionally, these immune suppressed patients often require frequent hospital admissions 
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for other opportunistic infections. They therefore represent a conduit between the 
community and health care institutions allowing for nosocomial pathogens to be 
transmitted at community level and vice versa. MTB strains isolated from in-patients do 
not exclude the possibility of similar strains circulating in the community. Genotyping 
techniques allow the possibility of studying the molecular epidemiology of MTB within a 
community and between community and health care institutions. This provides useful 
information in the analysis of outbreaks. It also facilitates analysis of complex transmission 





















MATERIALS AND METHODS 
 
3.1 Geographical Location of Source of Isolates 
The Msinga sub-district is a rural area situated in KwaZulu-Natal and comprises a 
predominantly indigent Zulu population. Tugela Ferry is the only town in this sub-district 
which is home to the Church of Scotland Hospital (CoSH). This hospital is a district 
hospital with 355 inpatient beds and in addition serves as a referral facility for 14 clinics. 
CoSH attends to patients which are referred by the clinics. Isolates for this study were 
collected from patients seeking in-patient or outpatient health services at this hospital. 
 
3.2 Ethics Approval 
The study was approved by the Biomedical Research Ethics Committee at the University 
of KwaZulu-Natal (#BCA274/09) for bacterial isolates that were grown from specimens 
sent for routine clinical care. Patients were not asked to give informed consent at the time 
of the clinical encounters. Additionally, specimens that were collected that were part of 
clinical studies were covered under ethics numbers E313/05 and BFC 061/07. 
 
3.3 Mycobacterium tuberculosis isolates 
The selected isolates were from 2 time periods viz: 2005/2006 and 2008/2009. These were 
isolated from specimens obtained from in-patients and out-patients attending CoSH.  
 
2005/2006 
The isolates were obtained from patients participating in the prevalence study by Gandhi et 
al. (2006) and from patients who had been routinely tested for the purpose of further 
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clinical management. Isolates from all new cases of TB presenting to CoSH that were part 
of a prevalence study done by Gandhi et al. (2006) were selected; additional isolates from 




The isolates were obtained from patients participating in the Microscopic Observation 
Drug Susceptibility (MODS) Assay study by Shah et al. (2011). Isolates from new cases 
presenting to CoSH during 2008-2009 who were recruited into a MODS study were also 
selected.  
 
The isolates from these studies were stored in the laboratory at UKZN. Viable cultures 
were selected for further processing in this study. Access to clinical information for 
isolates used in this study was limited. 
 
3.4 Culture of stored isolates 
3.4.1 Retrieval of isolates 
All stored isolates were retrieved from the -70 degrees Celsius (°C) freezer and thawed to 
room temperature. The thawed isolates were revived by inoculation into Middlebrook 7H9 
(Becton Dickinson and Company, Difco Laboratories, USA) broth or mycobacterial 
growth indicator tubes (MGIT) (BD, USA). 
 
3.4.2 Inoculation of Middlebrook 7H9 broth 
Sterile free-standing tubes containing 5ml of Middlebrook 7H9 (BD, Difco Laboratories, 
USA) broth supplemented with  oleic acid-albumin-dextrose-catalase (OADC) (BD, USA) 
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and made selective by adding the following antibiotics: Polymixin B (200.000 IU/L) 
(Sigma-Aldrich, USA), Amphotericin B (20mg/L) (Sigma-Aldrich, USA), Carbenicillin 
(100mg/L) (Sigma-Aldrich, USA) and Trimethoprim (20mg/L) (Sigma-Aldrich, USA) 
were added. Approximately 100µl of the isolate was inoculated into Middlebrook 7H9 
(BD, Difco Laboratories, USA) broth using a glass pasteur pipette. Tubes were incubated 
for 3-6 weeks at 37°C until growth was observed. 
 
3.4.2.1 Culture onto Middlebrook 7H11 agar plates 
Upon observation of growth in Middlebrook 7H9 (BD, Difco Laboratories, USA) broth, 
culture was aspirated, using a sterile glass pasteur pipette and inoculated onto Middlebrook 
7H11 (BD, Difco Laboratories, USA) agar plates. A sterile quadloop was used to streak the 
inoculum across the entire plate. Plates were heat sealed in gas permeable bags and 
incubated for 3 weeks at 37°C in a regular incubator. Plates were viewed after 3 weeks for 
the presence of MTB colonies.   
 
These cultures were used to perform drug susceptibility testing (DST) and to extract DNA 
for spoligotyping. 
 
3.4.2.2 Culture onto Lowenstein Jensen (LJ) slants 
Upon observation of growth in Middlebrook 7H9 broth, culture was aspirated using a 
sterile glass pasteur pipette and inoculated onto LJ slants (BD, USA). The LJ slants were 
inverted a few times to allow culture to spread across the surface of the slant. The caps of 





These cultures were used to extract DNA for IS6110 RFLP. 
 
3.5 Culture Confirmation 
Identification to species level of the growth on Middlebrook 7H11 (BD, Difco 
Laboratories, USA) agar plates was done using two biochemical tests. 
 
3.5.1 Nitrate test 
Sterile tubes were labelled with isolate numbers and 500µl of nitrate broth was aliquoted 
into each tube. Using a sterile quadloop a loopful of culture was scraped off the 
Middlebrook 7H11 (BD, Difco Laboratories, USA) agar plate and suspended into the tubes 
containing nitrate broth. Tubes were incubated at 37°C for 2 hours. Following incubation, 
1 drop of concentrated hydrochloric acid (HCl) (Merck, SA) followed by 2 drops of 0.2% 
sulfanilimide (Sigma-Aldrich, USA)  (nitrite1) solution and 2 drops of 0.1% N-(naphthyl) 
ethylenediamine dihydrochloride (Sigma-Aldrich, USA) (nitrite2) solution was added to all 
tubes. Tubes were observed for a colour change, any shade of pink indicated a positive 
result (Clinical Microbiology procedures handbook volume 2, 2004a). 
 
H37Rv laboratory strain was used as a positive control and a tube containing no culture 
was used as a negative control.  
 
3.5.2 Niacin test 
This was performed as described in the Clinical Microbiology procedures handbook 




A drop of cyanogen bromide (Sigma-Aldrich, USA) was added onto a lawn of confluent 
growth followed by a drop of aniline (Sigma-Aldrich, USA) on top of the cyanogen 
bromide. Plates were left to stand for 5 minutes and thereafter observed for the presence of 
a colour change, a shade of yellow indicated a positive result. 
 
H37Rv was used as a positive control and uninoculated culture medium as negative 
control. 
 
If both nitrate and niacin tests were positive, this confirmed the culture as being MTB. 
 
3.6 Drug Susceptibility Testing 
 
3.6.1 1% Modified Proportion method 
This was done as described in the Clinical Microbiology procedures handbook volume 2 
(2004b) using the indirect method, with slight modifications. 
 
This method is the gold standard for susceptibility testing of MTB. Colonies from a 3 week 
culture were used and a bacterial suspension in PBS with, 0.05% Tween-80 (Merck, SA) 
and 4 glass beads (diameter: 5mm) was prepared by vortexing tubes. The remaining 
clumps were allowed to settle after which the top layer was siphoned off. The harvest was 
matched to a McFarland standard 1 by adding PBS. Three 10-fold serial dilutions were 
done by adding 0.5ml of the suspension to 4.5ml of sterile triple distilled water to obtain an 
inoculum suspension of 10
-4
 colony forming units per ml (cfu/ml). Of these suspensions, 
100µl was inoculated on quadrants of the Middlebrook 7H10 (BD, Difco Laboratories, 





cfu/quadrant. Plates were allowed to dry for 30 minutes and sealed in gas 
permeable bags and incubated at 37°C in a CO2 incubator. 
 
Susceptibility tests were read after 3 weeks. The concentrations of anti-TB drugs used 
were: Isoniazid (INH) (Sigma-Aldrich, USA): 1µg/ml, Rifampicin (Sigma-Aldrich, USA): 
1µg/ml, Ethambutol (Sigma-Aldrich, USA): 7.5µg/ml, Streptomycin (Sigma-Aldrich, 
USA): 2µg/ml, Ofloxacin (Sigma-Aldrich, USA): 2µg/ml, Kanamycin (Sigma-Aldrich, 
USA): 5µg/ml, Ethionamide (Sigma-Aldrich, USA): 5µg/ml, Capreomycin (Sigma-
Aldrich, USA): 10µg/ml. 
 
A strain was classified as susceptible to a drug if <1% of growth was present on drug 
containing quadrants as compared to the growth present on the drug free control quadrant 
and resistant if the number of colonies on the drug containing quadrant was >1% of 
colonies that were present on the control quadrant. 
 
Laboratory strains with known susceptibilities were used as controls. H37Rv was used as a 
susceptible control and A169 was used as a resistant control. 
 
3.7 Spoligotyping 
Spoligotyping was performed as previously described by Kamerbeek et al. (1997) and 







3.7.1 DNA Isolation 
This method was done as described previously by Van Soolingen et al. (1991) and 
following the procedure outlined in the Spoligotyping Manual version 4 (2002), with slight 
modifications. 
 
3.7.1.1 Cetyltrimethylammonium bromide – Sodium chloride (CTAB-NaCl) method 
Growth from Middlebrook 7H11 (BD, Difco Laboratories, USA) agar plates was harvested 
using a sterile quadloop and suspended into 2ml micro-centrifuge tubes (Eppendorf) 
containing 500µl of 1xTris-EDTA (TE) buffer (Appendix 1.1). Cultures were heat killed at 
80°C for 30 minutes. 50µl of lysozyme (Sigma-Aldrich, USA) of concentration 10mg/ml 
(Appendix 1.2) was added to each sample which was then incubated in a 37°C water bath 
for 1 hour. Following this, 75µl of proteinase K (Roche Diagnostics, Mannheim, Germany) 
of concentration 10mg/ml (appendix 1.3) and 10% Sodium Dodecyl Sulfate (SDS) (Sigma-
Aldrich, USA) solution (appendix 1.4) were added to each sample, vortexed and incubated 
at 65°C for 10 minutes. Then 100µl of 5M Sodium Chloride (NaCl) (Sigma-Aldrich, USA) 
solution (appendix 1.5) was added and the tube was vortexed for few seconds after which 
100µl of pre-warmed CTAB-NaCl (Sigma-Aldrich, USA) solution (appendix 1.6) was 
added. The tube was vortexed until its contents turned milky. This was followed by 
incubation at 65°C for 10 minutes. Chloroform (Sigma-Aldrich, USA): Isoamyl alcohol 
(Sigma-Aldrich, USA) (24:1) solution (appendix 1.7) was added followed by vortexing 
and centrifugation for 20 minutes at 12000 rpm. The supernatant was transferred into a 
clean 1.5ml micro-centrifuge tube (Eppendorf) and 500µl of Isopropanol (Sigma-Aldrich, 
USA) was added to each tube. Samples were mixed by inverting tubes and the contents, 
was observed for thread formation. If a thread was visible, tubes were centrifuged for 30 
minutes, the supernatant discarded and the pellet washed with 1ml of 70% ethanol (Merck, 
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SA) (appendix 1.8). The tubes were then inverted, centrifuged for 5 minutes and the 
ethanol was discarded. The pellet was washed again in 500µl of 70% ethanol (Merck, SA) 
and the steps described for the previous wash were repeated. Pellets were left to dry for 10 
minutes at room temperature and the size was measured visually. Appropriate amounts of 
1xTE buffer were added to each pellet and stored at 4°C overnight or until further use. 
 
3.7.1.2 Gel Electrophoresis  
Estimation of DNA concentration and assessment of DNA quality 
A 1% agarose gel (appendix 1.9) was made using 1x Tris-Borate-EDTA (TBE) buffer 
(appendix 1.10). The agarose (Lonza, USA) was dissolved in 1xTBE buffer by heating in a 
microwave. The solution was allowed to cool and ethidium bromide (Sigma-Aldrich, 
USA) solution (appendix 1.11) was added. A casting tray and a 20 well comb were wiped 
with 70% ethanol. The casting tray was taped around the edges and the agarose solution 
poured in and allowed to set at room temperature. Once the gel had solidified the tape and 
comb were removed and the casting tray containing the gel was placed into an 
electrophoresis tank (Hoefer) containing 1xTBE buffer. A 3-5µl volume of sample loading 
dye (appendix 1.12) was added to a piece of parafilm for each DNA sample and 1µl of 
each DNA sample was mixed with the dye and loaded into a well of the gel. 
Electrophoresis was performed at 100 volts (V) for 30-45 minutes.   
 
The Syngene gel documentation system and Gene Snap software package were used to 
photograph and print pictures of the gels. The pictures were used to estimate the 





3.7.2 Polymerase Chain Reaction (PCR) of the Direct Repeat (DR) region 
Genomic DNA isolated from the MTB cultures was used as target DNA, to amplify the DR 
region. PCR was done a day before hybridisation and PCR products were stored at 4°C. 
The PCR mastermix contained the following reagents: nuclease free water, colourless 
GoTaq flexi buffer (Promega, Madison, WI, USA), PCR nucleotide mix (Roche 
Diagnositics, Mannheim, Germany), 20 pmol of each primer DRa (biotinylated) and DRb 
(Whitehead Scientific, IDT, Iowa) and GoTaq DNA Polymerase (Promega, Madison, WI, 
USA). The mastermix was aliquoted into PCR tubes and DNA added to each tube. The 
tubes were centrifuged using a micro-centrifuge (Eppendorf) and placed into the 
thermocycler (Applied Biosystems) for amplification. The following cycling conditions 
were used: 3 minutes at 96°C, 1 minute at 55°C and 30 seconds at 72°C for 20 cycles. 
 
3.7.3 Hybridisation 
For hybridisation, 20µl of each PCR product was diluted in 150µl 2xSSPE/0.1% SDS 
(appendix 2.1). The diluted PCR products were heat-denatured for 10 minutes at 99°C and 
thereafter immediately cooled on ice. The membrane (Ocimum Biosolutions, India) was 
washed for 5 minutes at 60°C in 250ml of 2xSSPE/0.1% SDS. The membrane and a 
support cushion (Ocimum Biosolutions, India) were placed onto the mini-blotter, so that 
the slots were perpendicular to the applied oligonucleotides present on the membrane. The 
residual fluid in the slots of the mini-blotter was removed by aspiration. The diluted PCR 
products were pipetted into the slots in such a way that the mini-blotter channels were 
perpendicular to row of the oligonucleotides. Hybridisation was done for 1 hour at 60°C.  
Samples were removed by aspiration and plastic forceps were used to remove the 




3.7.4 Washing of the membrane and incubation with the conjugate 
Following hybridisation the membrane was washed twice using 250ml of 2xSSPE/0.5% 
SDS (appendix 2.2) for 10 minutes at 60°C. The membrane was allowed to cool in a 
plastic container to prevent inactivation of the peroxidase that followed. Streptavidin-
peroxidase conjugate (Roche Diagnostics, Mannheim, Germany) was added to 20ml of 
2xSSPE/0.5% SDS. The membrane was incubated in this solution for 55 minutes at 42°C 
in its plastic container. The membrane was washed twice using 250ml of 2xSSPE/0.5% 
SDS for 10 minutes at 42°C and thereafter washed twice using 250ml of 2xSSPE 
(appendix 2.3) for 5 minutes at room temperature.   
 
3.7.5 Detection 
This was performed in the darkroom. For detection of the hybridised DNA, the membrane 
was submerged for 1 minute in 10ml of enhanced chemi-luminescence (ECL) detection 
solution (Amersham, Buckinghamshire, UK). The membrane was wrapped in plastic and 
wiped with a tissue to remove bubbles and placed into a hypercassette (Amersham, 
Buckinghamshire, UK), followed by exposure of a hyperfilm (Amersham, 
Buckinghamshire, UK) to it for 30 minutes. The hyperfilm was removed from the 
hypercassette and placed into developer (Agfa-Gevaert, Belgium) until spoligotype 
patterns appeared. Thereafter the film was placed into fixer (Agfa-Gevaert, Belgium) until 
the hyperfilm had a clear background and rinsed with tap water. 
 
3.7.6 Regeneration of the membrane 
For repeated use of the membrane, the membrane was washed twice by incubation in 1% 
SDS solution (appendix 2.4) for 30 minutes at 80°C. The membrane was washed in 20mM 
EDTA (Sigma-Aldrich, USA) (appendix 2.5) pH8, for 15 minutes at room temperature on 
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an orbital shaker (Stuart). The membrane was sealed in plastic to prevent dehydration and 
stored at 4°C until further use. 
 
3.7.7 Analysis of Spoligotying Patterns 
Spoligotyping patterns were compared to the international SpolDB4 database. The patterns 
were entered in a binary format onto the SITVIT database (Pasteur Institute of 
Guadeloupe: http://www.pasteur-guadeloupe.fr:8081/SITVIT/DEMO) which is an updated 
version of the SpolDB4 database. The corresponding shared international type (SIT) was 
identified for each isolate. The SpolDB4 database was also used to classify isolates into 
lineages and sub-lineages (Brudey et al., 2006). Isolates which had a unique spoligotype 
pattern and were not found on the international database were classified as ‗orphans‘ 
(Mathuria et al., 2007; Mulenga et al., 2010). Dendrograms were constructed using the 
Bionumerics version 3.5 software (Applied Maths, Kotrijk, Belgium). The dendrogram 
showed how spoligotyping patterns clustered and their degree of similarity. 
 
3.8 IS6110 RFLP 
Genotyping by IS6110 RFLP was performed as previously described by Van Embden et al. 
(1993) with a few modifications. 
 
3.8.1 DNA Isolation  
This was done using the CTAB-NaCl method, as previously described by Van Soolingen et 
al. (1991) with slight modifications. 
 
MTB colonies were scraped off LJ slants using a sterile swab and suspended into 2ml 
micro-centrifuge tubes (Eppendorf) containing 500µl of sterile distilled water. The bacteria 
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were heat killed at 80°C in a water bath for 30 minutes following which 70µl of 10% SDS 
and 50µl of proteinase K (10mg/ml) were added to each to tube. Tubes were incubated in a 
water bath at 60°C for 1 hour. The 5M NaCl and CTAB-NaCl solutions were prewarmed 
at 60°C and 100µl of each solution was added to each tube and mixed thoroughly with its 
contents by inverting the tubes a few times. The tubes were then incubated at 60°C for 15 
minutes and its contents frozen at -20°C for 15 minutes. The reaction mixtures were then 
defrosted at 60°C and 700µl of Chloroform-Isoamyl alcohol (24:1) solution was added to 
each tube and inverted several times until the contents turned milky. Tubes were 
centrifuged for 10 minutes at 12000 rpm. The upper aqueous supernatant was transferred to 
1.5ml micro-centrifuge tubes (Eppendorf) which contained 700µl of isopropanol. Tubes 
were inverted several times and placed in a -20°C freezer for 30 minutes, followed by 
centrifugation for 10 minutes at room temperature at 12000 rpm. The isopropanol was 
discarded and the pellet was washed with 70% ethanol and centrifuged for 10 minutes at 
12000 rpm. The ethanol was discarded and the pellets were dried in a DNA concentrator 
for 4 minutes. Approximately 35-55µl of 1xTE buffer was added to each tube depending 
on the pellet size. Tubes were rotated on an orbital shaker for 30 minutes to facilitate 
dissolving of the pellets. A 5µl volume of each DNA sample was electrophoresed on a 1% 
agarose gel as previously described, to estimate DNA concentration (3.7.1.2).   
 
3.8.2 Restriction 
The genomic DNA was digested with PvuII restriction endonuclease that cleaves the 
IS6110 sequence once. 
 
The approximate DNA concentration was estimated visually from pictures obtained and 
the amount of sample and water to be used were calculated to have a final volume of 22µl.  
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Appropriate volumes of sterile distilled water were added to each sterile 1.5ml micro-
centrifuge tube. Thereafter 2.5µl of buffer (Roche Diagnostics, Mannheim, Germany) was 
added to each tube, followed by the appropriate volume of each DNA sample, followed by 
1.5µl of PvuII enzyme (Roche Diagnostics, Mannheim, Germany). Each sample was 
mixed using a pipette and then placed onto a floater and incubated in a water bath at 37°C 
for 4 hours. 
 
3.8.2.1 Gel Electrophoresis 
Separation of DNA fragments  
A 1% agarose gel was prepared using 1xTBE buffer as described previously (3.7.1.2) but 
without adding ethidium bromide. The gel was allowed to cool. A casting tray and a comb 
were wiped with 70% ethanol. The casting tray was taped around the edges and the comb 
was placed at an appropriate level from the base of the tray. The agarose solution was 
poured into the casting tray and allowed to solidify at room temperature.    
 
On completion of the incubation period samples were removed from the water bath and a 
volume of 5µl of sample loading dye was added to each tube. Samples were quick-spun in 
a micro-centrifuge and loaded into wells 2-18 and 20. The Jacks standard molecular weight 
marker was loaded into wells 1 and 19, this marker served as the external reference. The 
gel was run at 100V for 45 minutes and at 36V overnight. 
 
3.8.3 Southern Blotting 
This was performed using the vacuum method. It involved the transfer of 
electrophorectically separated fragments to a Hybond N
+




The membrane was cut to the size of 15x20cm and placed into a glass container containing 
sterile distilled water. This was followed by a 5 minute washing step of the membrane in 
10xSSC solution (appendix 3.1) on an orbital shaker at room temperature. The vacuum 
blotting unit (Vacugene) was set up by placing the porous support (Amersham, 
Buckinghamshire, UK) onto the blotting unit correctly, followed by placing the membrane 
on top. The plastic mask (Amersham, Buckinghamshire, UK) was then aligned accordingly 
over the edges of the membrane. The gel was removed from the electrophoresis tank and 
gently slid onto the membrane. The vacuum pump was started and once it reached 55cm 
bar a 1:100 HCl solution (appendix 3.2) was poured over the gel and the vacuum applied 
for 20 minutes. The HCl solution was removed by tilting the blotting unit and aspirated 
using a suction device. The next solution called soak I (appendix 3.3) was poured over the 
gel and the vacuum applied again for 20 minutes. The aspiration step was repeated as 
previously and the soak II solution (appendix 3.4) was poured over the gel followed by 
application of the vacuum for 20 minutes and aspiration. The next solution 10xSSC 
(appendix 3.1) was poured over the gel, the vacuum was increased to 65cm bar and applied 
for 1 ½ hours. At all times the gel was completely covered with the appropriate solution 
used.  
 
On completion of blotting, the last solution was removed by aspiration and the gel 
removed and discarded. The membrane was allowed to air dry on paper towel for 5 
minutes and thereafter placed into the UV cross-linker and exposed by using a preset 







Enhanced chemi-luminescence (ECL) direct system was used, the method is based on 
horse-radish peroxidase labelling of the probe.  
 
The membrane was pre-hybridised using 25-30ml of hybridisation buffer (Amersham, 
Buckinghamshire, UK) (appendix 3.5), rotating for 30 minutes in a hybridisation oven at 
42°C. In a micro-centrifuge (Eppendorf) tube 10µl of the probe was mixed with 5µl of 
sterile distilled water, boiled for 5 minutes and placed on ice for 10 minutes. Equal 
volumes of DNA labelling reagent (Amersham, Buckinghamshire, UK) and glutaraldehyde 
(Amersham, Buckinghamshire, UK) were added to the probe mixture and incubated in a 
water bath at 37°C for 10-15 minutes. Hybridisation buffer covering the membrane was 
mixed with the probe and this mixture was then poured back into the hybridisation bottle 
containing the membrane. The hybridisation took place overnight at 42°C in a 
hybridisation oven (Stuart) on a bottle rotisserie. 
 
The hybridisation buffer was discarded the next day and the membrane was rinsed with 
primary wash buffer (appendix 3.6) which was discarded. Another volume of primary 
wash buffer was added to the membrane followed by incubation for 30 minutes at 42°C. 
The membrane was rinsed with 2xSSC solution (appendix 3.7) and transferred to a glass 
container. Two 5 minute washes with 2xSSC solution were applied at room temperature on 
an orbital shaker (Stuart). The final solution was discarded and the membrane was 







The banding patterns were detected by ECL. 
 
This was performed in the darkroom, following the same procedure described for 
spoligotyping detection process. For preparation of the membrane, it was placed into the 
hypercassette. The hypercassette was closed and the hyperfilm was exposed for 2 minutes.  
The hyperfilm was removed and placed into developer until all bands appeared and then 
placed into fixer until the background was clear. It was then rinsed with tap water. A 
second exposure was done and the timing depended on the intensity of the bands from the 
first exposure. The membrane was stored in plastic upon completion. 
 
3.8.6 Polymerase chain reaction (PCR) 
This was performed to prepare the DNA probe. It involved preparation of PCR fragments 
to be used as a probe. 
 
The mastermix for the PCR contained the following: 470µl nuclease free water, 10µl INS1 
and 10µl INS2 primers (Whitehead Scientific, IDT, Iowa), 10µl template DNA and 500µl 
Choice Taq mastermix (Denville Scientific, New Jersey, USA). Each PCR tube contained 
100µl of template DNA and mastermix. The cycling conditions were 5 minutes at 94°C, 30 
seconds at 94°C, 30 seconds at 55°C and 1 minute at 72°C, for 30 cycles. The PCR 
products were examined by electrophoresis using a 1% agarose gel as described previously 
for DNA estimation (3.7.1.2).  If the correctly sized fragments were obtained the probe was 





3.8.7 Analysis of IS6110 RFLP patterns 
The banding patterns were analysed visually and by means of a computer assisted program. 
The Bionumerics version 3.5 software (Applied Maths, Kortijk, Belgium), was used for the 
analysis of IS6110 RFLP patterns. The construction of dendrograms was done using the 
unweighted pair group clustering method of averages (UPGMA) and the dice coefficient. 
The dendrogram showed how fingerprints clustered and their degree of similarity. 
 
A cluster was defined by two or more isolates which had IS6110 RFLP banding patterns 
that were identical (Glynn et al., 1999; Murase et al., 2010). Isolates with unique patterns 
were considered to be non-clustered. A family of RFLP patterns is defined as a group of 
patterns with more than 4 IS6110 copies, differing by less than 1/3 of the hybridising bands 
or sharing 2/3 of hybridising bands which is equivalent to a similarity index of ≥ 65% 


















4.1 Antimicrobial susceptibility of isolates  
 
A total of 67 isolates were retrieved from storage for the period 2005/6. Using the 1% 
proportion method, these isolates were classified into categories as shown in Tables 1a, b, 
c. There were 2 isolates that were resistant to INH only (Table 1a). Of the MDR isolates 
(Table 1b), the susceptibility profile varied for the antimicrobials tested other than INH and 
rifampicin. There were no pre-XDR isolates identified. Most of the XDR isolates were 
resistant to all tested antimicrobials, there were 2 isolates which were susceptible to 





 I: Isoniazid    R: Rifampicin     E: Ethambutol    S: Streptomycin            














 I: Isoniazid     R: Rifampicin       E: Ethambutol      S: Streptomycin     









 I: Isoniazid     R: Rifampicin       E: Ethambutol      S: Streptomycin     
O: Ofloxacin   K: Kanamycin      C: Capreomycin   Et: Ethionamide 
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A total of 32 isolates were retrieved from storage for the period 2008/9. Using the 1% 
proportion method, these isolates were classified into susceptibility categories as shown in 





 I: Isoniazid     R: Rifampicin       E: Ethambutol       S: Streptomycin     
O: Ofloxacin   K: Kanamycin      C: Capreomycin    Et: Ethionamide 
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4.2 SITs and Drug Susceptibility Profiles 
 
Among the susceptible isolates for the periods 2005-2006 and 2008-2009, 4 SITs were 
predominant. SIT53 accounted for 25% (7/28) of the isolates, SIT34 for 7.1% (2/28), SIT1 
for 21.4% (6/28) and SIT33 for 10.7% (3/28). There was one single isolate in the 2005-06 
group which belonged to SIT59. The 2008/9 group contained 9 such isolates which fell 
into SIT21, SIT73, SIT39, SIT136, SIT137, SIT563, SIT811, SIT815 and 1 orphan pattern 
(Tables 2a and 2b).  
 
Among the MDR MTB isolates, SIT34 was the predominant pattern in 2005/6 and 2008/9:  
68% (14/22) and 40% (2/5) respectively. Nine percent (2/22) of MDR MTB isolates in 
2005/6 and 20% (1/5) in 2008/9 displayed the SIT53 pattern. The SIT60 accounted for 
23% (5/22) of isolates for 2005/6 and 20% (1/5) 2008/9 group. The fifth isolate from 
2008/9 and 5% (1/22) from 2005/6 showed the SIT831 pattern. (Tables 2a and 2b) 
 
The SIT60 pattern accounted for 94% (30/32) of XDR TB isolates from 2005/6 and 58% 
(7/12) of XDR TB isolates from 2008/9 (Table 2a and 2b). The other 2 XDR isolates from 
2005/6 belonged to SIT53 (Table 2a). The five XDR isolates from 2008/9 not belonging to 



































4.3 Spoligotypes and Lineages 
 
Figure 1 is a scanned copy of the hyperfilm of the predominant spoligotypes obtained in 
this study. Hyperfilms showing additional spoilgotypes are contained in appendix 4. 
 
43 spacer oligonucleotides 
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Figure 1: Predominant Spoligotype patterns among the isolates 
Lane 2: SIT34 
Lane 4: SIT1 
Lane 8: SIT53 
Lane 9-11: SIT60 
Positive controls: Lane 20: H37Rv, Lane 21: M.bovis 







































1 Beijing □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ 
33    LAM3 ■■■■■■■■□□□■■■■■■■■■□□□□■■■■■■■■□□□□■■■■■■■ 
34 S ■■■■■■■■□□■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 
53 T1 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 
60 LAM4 ■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■■□□□□■■■□■■■ 
21 CAS1-KILI ■■■□□□□■■□■■■■■■■■■□□□□□□□□□□□□□□□□■■■■■■■■ 
39 T4-CEU1 ■■■■■■■■■■■■■■■■■■□■■■□□■■■■■■■■□□□□■□□■■■■ 
59 T5-MADZ ■■■■■■■■■■■■■■■■■■■■□□□□■■□□□□■■□□□□■■■■■■■ 
73 T2-T3 ■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■□□□□■■■□■■■ 
136 T1 ■■■■■■■■■■■□□□□□■■■□□□□□■□■■■■■■□□□□■□□■■■■ 
137 X2 ■■■■■■■■■■■■■■■■■□■■■■■■■■■■■■■■□□□□■■□□□□■ 
563 U ■■■■■■■■■■■■■■■■■■■■■□□□□■■□□□□■■□□□□■■■■■■ 
811 LAM4 ■■■■■■■■■■■■■■■■■■■■□□□□■□□□□□■■□□□□■■■□■■■ 
815 LAM11-ZWE ■■■■■■■■■■■■■■■■■■■■□□□□■■□□□□■■□□□□■■■□■■■ 
831 S ■■■■■■■■□□■■■■□■■■■■■■■■■■■■■■■■□□□□■■■■■■■ 
1750 LAM4 ■■■■■■■■■■■■■■□■■■■■□□□□■■■■■■■■□□□□■■■□■■■ 
Orphan1 ■■■■■■■■■■■■■■□■■■■■□□□□■■■■■■■■□□□□■■□□■■■ 
Orphan 2 ■■■■■■■■■■■■■□□□□□■■■■■□■□□□□□□■□□□□■■■■■■■ 
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*Analysis done using the international spoligotype database SpolDB4 http://www.pasteur-
guadeloupe.fr:8081/SITVIT/DEMO 
a
 Shared international type number as describe in the spoligotype database SpolDB4 
b 
Strain family as assigned in the international spoligotype database SpolDB4 
c 
Spoligotype pattern with solid blocks indicating the presence of a spacer and empty 
blocks indicating the absence of a spacer. 
 
Figure 2 depicts the classification of the spoligotypes obtained in this study as compared to 
the international SpolDB4 database. Based on the spoligotype patterns, the isolates could 
be classified into lineages or sub-lineages. The S lineage is represented by SIT34 and 
SIT831 with the latter differing by omission of spacer 15 as compared to the former. The 
LAM4 sub-lineage contains SIT60, SIT811 and SIT1750. While the missing spacers 
between SIT60 and SIT811 consist of a block of 5, SIT1750 differs with only one missing 






















Figure 3 shows the spoligotype dendrogram for all isolates in the study. The predominant 








4.4 Differentiation of Isolates by IS6110 RFLP  
All sensitive and resistant strains were considered when clustering analysis was performed. 
A cluster was defined as two or more isolates with an identical IS6110 RFLP pattern. 
Strain clusters indicate clonal transmission of MTB. 
 
Among the susceptible isolates in this study, only (2/13) from 2005/6 clustered but did not 
belong to one of the families dominant in KZN (Table 3a). Of the 11 non-clustering 
isolates 4 belonged to the Beijing family of strains. None of the 15 susceptible isolates 
from 2008/9 belonged to an IS6110 RFLP cluster. Two belonged to the Beijing family 
(Table 3b).  
 
 A total of 22 MDR isolates from 2005/6 were analysed and 5 from 2008/9. Of the first 
group, 14 (64%) clustered. Of these, 3 showed the F15/LAM4/KZN family fingerprint 
while 11 belonged to the F28 family. The other 8 MDR TB isolates all had unique patterns, 
2 belonging to the F15/LAM4/KZN family and 3 to the F28 family. (Table 3a)  Two of the 
5 MDR isolates from 2008/9 formed a cluster and that cluster belonged to the F28 family 
(Table 3b). 
 
All 44 XDR TB isolates (32 from 2005/6 and 12 from 2008/9) belonged to the 
F15/LAM4/KZN family. Of these 43/44 (98%) clustered and the remaining 1 XDR (from 






Susceptibility Clustering Non-clustering Clustering Non-clustering Clustering Non-clustering Clustering Non-clustering
Susceptible 2 7 4
MDR 3 3 2 11 3
XDR 32
Total 2 10 35 2 11 3 4
Susceptibility Clustering Non-clustering Clustering Non-clustering Clustering Non-clustering Clustering Non-clustering
Susceptible 13 2
MDR 1 1 2 1
XDR 11 1
Total 14 11 2 2 1 2
Table 3b: IS6110 RFLP results from Tugela Ferry 2008/9
Other F15/LAM4/KZN F28 Beijing
Strain Families
F15/LAM4/KZN F28 BeijingOther
























Figure 4 is a scanned hyperfilm showing the IS6110 RFLP patterns obtained in the study.  
Hyperfilms showing additional IS6110 RFLP patterns are contained in appendix 5. 
 
  M     2   3    4     5     6    7     8    9   10  11   12  13  14   15        
 
Figure 4: IS6110 RFLP patterns for (2005-2006) and (2008-2009) 
Lane 1: Jack‘s standard molecular weight marker (0.7-15kbps) 
(2005-2006):  Lane 2-3: unique cluster                       Lane 12: unique patterns 
Lane 4-8: F15/LAM4/KZN family patterns                Lane 13: Beijing family pattern 
Lane 9-11: F28 family patterns 
(2008-2009): Lanes 14-15: unique patterns  
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Figure 5 shows the dendrogram that was generated for the IS6110 RFLP patterns. The 
predominant families and unique patterns are labelled accordingly. 
 



















4.5 Linking of Spoligotyping and IS6110 RFLP results 
 
Figure 6a and 6b shows further differentiation of isolates belonging to SIT60 by IS6110 
RFLP. All isolates in SIT60 belonged to the F15/LAM4/KZN family by IS6110 RFLP. 
The majority of XDR (36/37, 97%) and MDR (3/6, 50%) isolates were classified into 1 of 
2 clusters and the remaining IS6110 RFLP patterns differed by 1-3 bands from those in 
clusters.  
 
Figure 6a (2005/6) and 6b (2008/9): Further differentiation of isolates belonging to 
SIT60, by IS6110 RFLP and linked to Susceptibility profiles.  
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Figure 7 (2008/9): Further differentiation of isolates belonging to SIT1750 and 
orphan1, by IS6110 RFLP and linked to Susceptibility profiles 
 








Figure 7 shows further differentiation of isolates belonging to SIT1750 and an orphan 
group by IS6110 RFLP which were all XDR isolates from 2008/9. All 5 isolates showed 
IS6110 RFLP patterns belonging to the F15/LAM4/KZN family and all 5 were part of the 
dominant cluster of XDR TB isolates (Fig 6a). 
F15/LAM4/ KZN Variant 1 Cluster 
n=6 
F15/LAM4/ KZN Variant 4 
n=1 
XDR n=6 
MDR n=1 SIT60 (n=8) 
2008-2009 
















Figure 8a (2005/6) and 8b (2008/9): Further differentiation of isolates belonging to 
SIT53, by IS6110 RFLP and linked to Susceptibility profiles 
 
































Figure 8a and 8b displays the further differentiation by IS6110 RFLP of isolates that 
belonged to SIT53. A total of 12 isolates (10 from 2005/6; 2 from 2008/9) with varying 
susceptibility profiles belonged to this spoligotype. The 2 XDR TB isolates, both from 
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 Unique Patterns 
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SIT53 (n=2) 
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 Unique Patterns 
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 MDR n=1 
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All 3 MDR TB isolates had unique IS6110 RFLP patterns. Within the 7 susceptible 
isolates from 2005/6 there was an IS6110 RFLP cluster of 2 while the remaining 5 
susceptible isolates all had unique IS6110 RFLP patterns.   
 
Figure 9a (2005/6) and 9b (2008/9): Further differentiation of isolates belonging to 
SIT34 by IS6110 RFLP and linked to Susceptibility profiles 
 





















Figure 9a and 9b show the differentiation by IS6110 RFLP of isolates that belonged to 
SIT34. A total of 16 MDR and 2 susceptible TB isolates were present in SIT34. IS6110 
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RFLP analysis showed that 12 (70%) of the MDR TB isolates belonged the F28 cluster 
while the remaining 4 MDR TB isolates were unique, but 3 of the 4 had IS6110 RFLP 
patterns which also belonged to the F28 family. Three of the 4 unique MDR isolates 
differed by 1-3 bands from those in the F28 cluster. The 2 susceptible isolates and the 
remaining 1 MDR isolate had totally unique IS6110 RFLP patterns from those in the 
cluster. 
 
Figure 10a (2005/6) and 10b (2008/9): Further differentiation of MDR TB isolates 
belonging to SIT831 by IS6110 RFLP 
 















Figure 10a and 10b shows 2 MDR TB isolates belonging to SIT831 which had IS6110 
RFLP patterns which belong to the F28 family. The 1 MDR TB isolate from 2008-2009 




F28 Cluster MDR n=1 
SIT831 (n=1) 
2005-2006 
Unique Patterns MDR n=1 
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Figure 11a (2005/6) and 11b (2008/9): Further differentiation of isolates belonging to 
SIT1 by IS6110 RFLP and linked to Susceptibility profiles 
 

















Figure 11a and 11b shows the further differentiation by IS6110 RFLP of isolates that 
belonged to SIT1 which were all susceptible. IS6110 RFLP patterns for these isolates were 
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Figure 12a (2005/6) and 12b (2008/9): Further differentiation of susceptible isolates 
belonging to SIT33 by IS6110 RFLP 
 














Figure 12a and 12b shows the further differentiation by IS6110 RFLP of isolates that 
belonged to SIT33 which were all susceptible. IS6110 RFLP patterns for these isolates 
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Figure 13a (2005/6) and 13b (2008/9): Further differentiation of single susceptible TB 
isolates belonging to various SITs by IS6110 RFLP 
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Figure 13a and 13b shows further differentiation by IS6110 RFLP of single susceptible TB 







































Figure14 shows the dendrogram that was generated for the combined spoligotypes and 













Studies describing the frequency and distribution of MDR and XDR MTB genotypes in 
South Africa are limited (Stavrum et al., 2009). In this study we investigated the molecular 
epidemiology of MTB in Tugela Ferry in KZN, to ascertain whether the cases of MDR 
including XDR TB are the result of clonal spread or simultaneous de novo development of 
resistance in different strains. Two genotyping methods were employed viz: spoligotyping 
and IS6110 RFLP. A total of 99 isolates, 67 from 2005/6 and 32 from 2008/9, with varying 
susceptibility profiles were analysed. Our results show that the spread of XDR TB in 
Tugela Ferry was clonal during both study periods. The strain responsible for transmission 
was a strain belonging to the F15/LAM4/KZN family, which has been responsible for 
about 1/3 of all MDR TB cases in KZN since 1994 (Pillay and Sturm, 2007). Our 
conclusion that this XDR TB epidemic in Tugela Ferry is due to clonal spread, rather than 
de novo amplification of drug resistance in different MTB strains is supported by the 
cluster analysis of the isolate genotypes. This analysis showed that 43 out of the 44 XDR 
TB isolates analysed were clustered and belonged to the same F15/LAM4/KZN genotype, 
while the remaining isolate was closely related, differing by only 1 band on the IS6110 
RFLP. In contrast, only 2 out of the 28 susceptible or INH mono-resistant isolates were 
clustered, while 16 out of the 27 MDR isolates were clustered, belonging to either 
F15/LAM4/KZN or F28 genotypes.     
 
The isolates that were genotyped in this study were from inpatients and outpatients. We do 
not have enough clinical, epidemiological and contact tracing information to determine the 
source of the XDR strain circulating in Tugela Ferry. It is unclear whether the isolate first 
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appeared in the community or in CoSH. Despite the relatively small numbers, this study 
adds to information on the molecular epidemiology of MTB strains circulating in the 
Tugela Ferry area and provides insight as to which genotypes are primarily responsible for 
infections amongst the local population. 
 
Spoligotyping of the XDR TB strains revealed that the LAM4 sub-lineage which is part of 
the LAM lineage and represented by SIT60, was the predominant genotype. Although the 
first XDR isolate was found in 2001 (Pillay and Sturm, 2007), the first spoligotyping of 
such isolates in South Africa was performed on the isolates from the first XDR TB  
patients identified in Tugela Ferry in 2005 (Ghandi et al, 2006). The spoligotyping results 
revealed that all the XDR isolates belonged to the KZN family which corresponded to the 
spoligotype pattern SIT60 (Ghandi et al., 2006). A retrospective analysis of isolates 
obtained between 1994 and 2002 from patients in KZN, revealed that strains with the 
SIT60 pattern have been present in KZN since at least 1994. These strains had a unique 
RFLP fingerprint belonging to the F15/LAM4/KZN genotype; at this time point, the strains 
with the SIT60 pattern was most prevalent amongst the MDR isolates from patients in the 
province of KZN (Pillay and Sturm, 2007). Isolates with the SIT60 spoligotype pattern in 
our study accounted for the vast majority of XDR TB cases and this correlates with 
previous studies in Tugela Ferry, in which this spoligotype was responsible for the 
majority of re-infections with XDR-TB (Andrews et al., 2008). In this study all of XDR 
cases were infected with one of the IS6110 genotypes that evolved out of the original 
genotype reported from 1994. In contrast, almost half of the MDR isolates with the SIT60 




A study by Mlambo et al. (2008) provides genotypic information on XDR TB strains in 7 
of the 9 provinces in South Africa. The study found XDR TB in 4 of the 7 provinces. The 
study showed that XDR TB strains in South Africa belong to seven different lineages. In 
Gauteng province and Limpopo province 3 of the 41 XDR TB isolates had the SIT60 
spoligotype pattern and belonged to the LAM4 sub-lineage. This spoligotype pattern has 
also been found in 12 countries in Europe, North and South America (Brudey et al., 2006; 
Filliol et al., 2003). The study concluded that de novo drug resistance rather than 
transmission was the predominant source of XDR TB cases (Mlambo et al., 2008). Our 
study implies that the factors driving the XDR TB epidemic locally in Tugela Ferry may 
differ from those in other regions of South Africa.  
 
Additional spoligotype patterns found in this study among the XDR TB isolates included 
the SIT53 spoligotype pattern which is representative of the T1 sub-lineage. In this study, 
the XDR isolates with the SIT60 and 53 patterns clustered with an identical RFLP pattern. 
Patterns which differ from those that cluster by 1 of the 2 techniques may be associated 
with mixed infections or may be the result of evolution of the DR region. Alternatively, 
our results may indicate that isolates with the SIT53 pattern are evolving and acquiring 
more resistance mechanisms.  
 
Our findings may be explained by the presence of multiple strains in the specimen. As with 
similar studies, we have not been able to rule out mixed infections with more than one 
MTB strain. This has the potential to result in false genotypes. The fact that this is a reality 
has been shown in several studies. Matsumoto et al. (2005) analysed a sweep of colonies 
from initial culture, as well as individually separated colonies using IS6110 RFLP and 
spoligotyping. Genotyping of the single colonies showed different patterns with varying 
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susceptibility to rifampicin. Analysis on the sweep of colonies did not detect differences. 
This suggested that dual infection with different MTB strains may occur.  Stavrum et al. 
(2009) showed that 53.6% isolates with the SIT53 pattern had a mixed MTB infection 
when analysed by 15 loci MIRU-VNTR. A recent study that included all culture confirmed 
cases of TB in KZN over an 18-month period, showed that mixed infections occurred in 
almost 7% of patients in 2006/2007 (Moodley et al., 2011). A limitation of the study was 
the inability to detect mixed infections since genotyping was performed on a sweep of 
colonies as opposed to single colonies. 
 
We report SIT53 to be responsible for a small proportion 6% (2/32) of XDR TB cases in 
2005-2006. These 2 XDR TB isolates were confirmed to be SIT53 on repeat testing. XDR 
TB re-infections with the SIT53 pattern were formerly reported in 17% of the cases in 
Tugela Ferry (Andrews et al., 2008). 
 
Among the XDR TB isolates obtained during the period 2008-2009,  two (16.7%) had the 
SIT1750 spoligotype pattern which like SIT60, belongs to the LAM4 sub-lineage and has 
only one spacer difference with SIT60.  Another three (25%) showed an orphan pattern 
i.e.: this pattern was not found on the international SpolDB4 database. However this 
pattern has major similarity with the SIT60 and SIT1750 spoligotype patterns, it has 
spacers 15, 21-24, 33-36, 39 and 40 absent. The orphan pattern has a difference of 2 
spacers as compared to the SIT60 spoligotype pattern, which are absent and a difference of 
1 spacer as compared to the SIT1750 spoligotype pattern is absent. 
 
XDR TB isolates from the period 2005/6 which had the SIT53 pattern and from 2008/9 
with the SIT1750 pattern and the orphan pattern which were similar to SIT60, these 
69 
 
patterns could be associated with evolution of the direct repeat (DR) region which occurs 
over time. Different mechanisms are involved which include IS6110 mediated mutations, 
point mutations, homologous recombination and duplication of direct variable repeat 
(DVR) sequences. In a study by Warren et al. (2002) the DR region was analysed for three 
independent evolving strain families. IS6110 mediated mutations and homologous 
recombination were responsible for changes in the DVR sequences. The frequency of 
change within the DR region seemed to be strain family specific and the mechanisms were 
dependent either on the DR region structure or the mutation rate of the strain family.  
Isolates in each strain family had specific DVR sequences deleted. These spoligotype 
signatures appeared to be unique for a specific strain family. Insertion of IS6110 into the 
DR region or spacer sequences results in deletion of the DVR sequence and influences the 
spoligotype pattern. IS6110 has the ability to prevent hybridisation of spacer sequences 
and inhibit PCR amplification. The spacers may be present and can be identified by 
sequencing. IS6110 has preferential integration loci in the DR region which are also strain 
family specific and enables the DR structure to influence evolution. Among the XDR TB 
isolates in this study which had great similarity with SIT60 and the characteristic spacers 
21-24, 33-36 and 40 absent, IS6110 could be responsible for the additional spacers being 
absent and evolution of the DR region may have occurred.    
 
Whilst the spoligotype patterns for the 44 XDR MTB isolates in this study differed as 
discussed above, IS6110 RFLP analysis showed that 43 isolates clustered with an identical 
IS6110 RFLP banding pattern corresponding to the F15/LAM4/KZN family, whilst 1 XDR 
TB isolate had an IS6110 RFLP banding pattern which differed by 1 band as compared to 
those in the predominant cluster. This could be associated with a time lapse and the 
evolution of the MTB genome over time since IS6110 elements have the ability to relocate 
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within the genome (McEvoy et al., 2007). Isolates from more recent years should be 
evaluated to establish if IS6110 patterns in XDR isolates have changed over time. 
Our results show that SIT34 which is representative of the S lineage was the predominant 
spoligotype among MDR TB isolates. The SIT53 (T1 sub-lineage), SIT831 (S lineage) and 
the SIT60 (LAM4 sub-lineage) spoligotypes were also present among the MDR MTB 
isolates. 
 
MDR TB genotypes belonging to 10 different lineages were identified in a study by 
Stavrum et al. (2009). The LAM lineage was the most common in the Eastern Cape, KZN, 
Mpumalanga and North West provinces.  
 
In a study by Chihota et al. (2010) the S lineage was most common in South Africa and 
was identified in 7% of the isolates. Information regarding MTB genotypes in South Africa 
is restricted to those areas where genotyping is performed. In a study by Streicher et al. 
(2004) which was conducted in the Western Cape the F28 family and SIT34 were 
associated with MDR TB cases as well as INH and rifampicin mono-resistant cases. In our 
study, the majority of the MDR TB strains belonged to the F28 family which implies that 
the spread of MDR may be clonal with respect to this strain family. While up till 2002 the 
F15/LAM4/KZN strain dominated amongst MDR cases (Pillay and Sturm, 2007), the data 
presented here suggest that F28 has taken over this role with F15/LAM4/KZN now 
dominating amongst the XDR cases. 
 
Further analysis of the genotype patterns of the MDR MTB isolates in this study revealed 
that a large F28 cluster and 4 unique patterns were present among the isolates that 
belonged to SIT34. The IS6110 RFLP patterns for isolates belonging to the F28 cluster and 
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those with unique patterns (3/4) had a high degree of similarity with the F28 patterns 
reported by Warren et al. (2002). 
 
The 6 MDR TB isolates which belonged to the SIT60 were further differentiated by 
IS6110 RFLP. IS6110 RFLP analysis revealed that 50% (3/6) still clustered but differed 
from the XDR TB cluster by 1 band. The other 50% (3/6) of MDR TB isolates in the 
SIT60 cluster had IS6110 RFLP patterns which differed by 1 band from each other and 
from the MDR and XDR TB cluster. All these isolates had IS6110 RFLP patterns that 
belonged to the F15/LAM4/KZN family.  
 
MDR TB isolates which belonged to SIT53 were further differentiated into unique patterns 
by IS6110 RFLP. Our genotyping results, suggest that most of the MDR TB cases in the 
Tugela Ferry area, result from clonal spread. A case for de novo resistance is more difficult 
to make since one cannot be sure whether isolates with a unique pattern among those 
studied are not part of a cluster of isolates of which have not been included. However, the 
evolution of, in particular F15/LAM4/KZN from MDR to XDR can only be explained by 
such de novo development followed by clonal spread. The F28 pattern was predominant 
amongst MDR TB strains circulating in this area. In addition another cluster which had 
IS6110 RFLP patterns belonging to the KZN family was present. The many non- clustering 
MDR TB isolates may be linked with de novo resistance. This challenges the concept that 
the use of fixed drug combinations like Rifafour prevent such events.  
 
In our study the majority of XDR isolates were of the KZN family. Previous reports have 
shown that the MDR form of the KZN family of strains is present in our area (Pillay and 
Sturm, 2007). The proportion of XDR TB in the Tugela ferry area has been reported to be 
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at least 3 times higher than any other district in the KZN Province (Moodley et al., 2011). 
This could represent an outbreak of XDR TB in the Tugela Ferry area which might explain 
the disproportionate number of KZN family XDR isolates compared with MDR isolates. 
 
The susceptible isolates in this study also had spoligotype patterns similar to those strains 
which were responsible for MDR and XDR TB spoligotypes i.e. SIT34 and SIT53. No 
SIT60 pattern was found among the susceptible isolates tested. One possibility is the fact 
that the sample size was limited and not representative of the entire community. Secondly, 
SIT60 may reflect an already mutated resistant isolate. The SIT1 is representative of the 
Beijing lineage. The Beijing lineage has worldwide distribution and has been responsible 
for both susceptible and drug resistant MTB infections. In our setting we found SIT1 only 
amongst susceptible isolates.  
 
Several SITs were present as single isolates (Figure 13a and 13b). Most of these SITs have 
also been reported from other African countries. 
 
The Latin-American Mediterranean (LAM) lineage can be divided into sub-lineages 
LAM1-LAM11 (Stavrum et al., 2009). The LAM3 (SIT33), LAM4 (SIT811) and LAM11-
ZWE (SIT59 and SIT815) sub-lineages have been found in susceptible TB isolates in this 
study. The LAM3 sub-lineage has been responsible for TB cases in the Western Cape 
Province, South Africa (Victor et al., 2004). The LAM11-ZWE sub-lineage has accounted 
for 57.8% of isolates from patients in Zimbabwe and it is likely to be identical to the 
recently described Meru family found in Tanzania (Brudey et al., 2006; Easterbrook et al., 




 The CAS1-KILI (SIT21) lineage is found in Tanzania (Kibiki et al., 2007). The X lineage 
(SIT137) which can be divided into X1-X3 sub-lineages is prevalent in United Kingdom, 
USA and former British colonies (Brudey et al., 2006).   
 
The ill-defined T lineage has been found on all continents (Brudey et al., 2006).  In a study 
by Chihota et al. (2010) the T1 sub-lineage was predominant within the T lineage.  The T1 
strains were found in different proportions among the following countries, 74.5% in 
Madagascar, 37.9% in Mozambique, 43.5% in South Africa, 57.5% in Tanzania, 85.7% in 
Zambia, 86.7% in Zimbabwe and all isolates from Namibia and Malawi. In this study the 
following SITs: SIT21 representative of the CAS-KILI lineage, SIT39 representative of the 
T4-CEU1 sub-lineage, SIT33 representative of the LAM3 sub-lineage, SIT73 
representative of the T2-T3 sub-lineage, SIT137 representative of the X2 sub-lineage, 
SIT563 representative of the U lineage, SIT811 representative of the LAM4 sub-lineage 
and SIT815 representative of the LAM11-ZWE have been identified and have also been 
found in a study conducted in South Africa by Stavrum et al.  (2009). 
 
The SITs found in South Africa have been found in neighbouring countries. The spread of 
these strains may be facilitated by cross border migration. A study conducted in 
Zimbabwe, Zambia and South Africa identified a predominant group of strains with a 
unique spoligotype pattern with spacers 21-24, 27-30 and 33-36 absent (Chihota et al., 
2007). Other studies in surrounding countries of South Africa have identified strains 
corresponding with those in this present study.   
 
Further differentiation by IS6110 RFLP was done for all susceptible isolates, but very few 
clustered. This is likely the result of the very small sample out of many patients infected 
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with susceptible isolates. A total of 16 unique patterns were found among the susceptible 
isolates which belonged to one of the four predominant SITs. In our study the Beijing 
strains have been associated with susceptible isolates and belong to the SIT1 and have a 
multi-band IS6110 RFLP fingerprint. Susceptible isolates which belonged to the SIT1 had 
differing IS6110 RFLP banding patterns but which had a similarity of ≥65% and therefore 
still belonged to a common family with their corresponding SIT1. Susceptible isolates 
within the respective SITs i.e. SIT33, SIT34 and SIT53 had IS6110 banding patterns which 
were similar. 
 
A total of 99 isolates which were classified into 18 SITs (8 SITs containing 2 or more 
isolates and 10 SITs containing only 1 isolate) were further genotyped by IS6110 RFLP. 
This revealed that 29 isolates had unique patterns and 61 had identical patterns to at least 1 
other isolate in this collection. Additionally 9 isolates had IS6110 RFLP patterns with 
approximately 95% similarity (i.e.1 band difference) to another isolate. A total of 42 
different RFLP patterns were seen amongst the 99 isolates. IS6110 RFLP analysis enabled 
further differentiation of MTB strain clusters identified by spoligotyping.  
 
Spoligotyping revealed that the LAM4, T1, S and Beijing families were predominant 
among this TB isolate collection. Out of 89 isolates that clustered by spoligotyping, 28 
could be further differentiated as unique strains by IS6110 RFLP. It is recommended that 
both techniques be used simultaneously to genotype MTB. The use of spoligotyping alone 
in this study would have resulted in assigning more isolates to clusters and underestimate 
the number of isolates with unique patterns. The use of IS6110 RFLP alone would 
distinguish unique patterns however isolates with less than 6 IS6110 copies are difficult to 
discriminate and supplementary genotyping techniques are required to analyse these.  
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Previous studies have shown that isolates which clustered by spoligotyping could be 
further differentiated into unique patterns by RFLP (Mathuria et al., 2007). Combining two 
genotyping methods reduced the fraction of clustering among the MDR and XDR TB 
isolates in our study with the IS6110 RFLP being more discriminatory.   
 
Further differentiation of the spoligotyping SITs by IS6110 RFLP revealed that within 
each SIT more distinct banding patterns among isolates were present, however although 
IS6110 RFLP patterns differed among isolates, the similarity of fingerprints were ≥65% 
among isolates sharing a common susceptibility profile, suggesting that the majority of 
strains still belonged to a common family within their corresponding SIT. 
 
In a study by Warren et al. (2002) it was shown that different isolates from the same strain 
family classified by IS6110 RFLP and isolates from different strain families were observed 
to converge to the same spoligotype pattern. Homologous recombination of IS6110 
elements led to deletion of DVR sequences and influenced spoligotype patterns. This 
evolution mechanism resulted in identical spoligotype patterns among different strain 
families.    
 
Tugela Ferry is known to have a high HIV TB co-infection prevalence. Patients in high TB 
incidence settings have shown to be more prone to mixed infections as a result of repeated 
re-infections (Richardson et al., 2002; Stavrum et al., 2009; Warren et al., 2004). Our 
study population is susceptible to contracting concurrent infections with different TB 
strains and our results suggest that this may occur. Further studies are required to evaluate 
the extent and implications of mixed bacterial populations in management of patients and 
in interpreting genotyping results.  
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There appears to be a substantial decrease in the proportion of XDR strains, comparing 
2005/6 to 2008/9. This may indeed reflect a decline in the prevalence in Tugela Ferry since 
increased TB control has intensified case finding and screening.  TB treatment teams have 
also been recruited to monitor treatment in the community. By strengthening TB control 
programs, the TB default rate has decreased and the treatment success rate has increased. 
Household contact tracing has also been implemented for MDR and XDR TB, trace teams 
visit households and screen contacts for sign and symptoms of TB. A community 
surveillance system monitors TB transmission, trace teams collect gps co-ordinates of all 
households which have MDR and XDR patients, which enables the mapping of the 
distribution and number of households affected. Intensive case finding programs in 
hospitals and the community have been established. Patients entering healthcare facilities 
are screened to identify TB suspects. Infection control policies are being carefully 
monitored and a decline in MDR and XDR TB in CoSH wards has been observed. 
Community based treatment programs help ensure successful completion of treatment, 
nurses visit those infected with MDR TB and administer 2
nd
 line agents by injection and 
also monitor doses of oral medication (TF CARES/Philanjalo). 
 
Spoligotyoing has been shown to be less discriminate than IS6110 RFLP in previous 
studies. Our study confirms this observation since strains with identical spoligotypes were 
further discriminated by IS6110 RFLP genotyping. However, IS6110 RFLP is labour 
intensive and has a slow turnaround time since prolonged incubation periods are required 
to generate high quality DNA.  The resolution of this technique is inversely proportional to 
the copy number of IS6110 elements with strains having less than six copies of IS6110 
being indiscriminate. Inter-laboratory analysis of RFLP patterns is tedious and specialised 
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software is required (Mathema et al., 2006). In this study 2 complementary genotyping 
methods were used in an attempt to overcome the limitations when used individually.  
 
Further studies to confirm the clonal spread of MDR and XDR TB strains described in this 
study should use genotyping methods such as MIRU:VNTR. A study by Murase et al. 
(2010) evaluated RFLP clusters of MDR and XDR TB using MIRU:VNTR. The results 
between RFLP and MIRU:VNTR correlated since 7 of the 9 RFLP clusters had identical 
MIRU:VNTR profiles. The remaining 2 clusters had a single locus variant i.e. 1 strain had 
1 locus difference in each cluster. The newly proposed standard which utilises 24 loci of 
tandem repeats has a comparable specificity to IS6110 RFLP and is faster and cheaper. 
Since the MIRU:VNTR method has demonstrated an ability similar to IS6110 RFLP 




While the Beijing strain shows a tendency to resistance in other geographic areas, in the 
Tugela Ferry area of KwaZulu-Natal, this family of strains is circulating in a susceptible 
form. The F15/LAM4/KZN strain family has dominated amongst MDR isolates from at 
least 1994 till 2002. The dominant MDR strain family is now F28, similar to the situation 
in the Western Cape. The F28 strain currently circulating as an MDR TB outbreak may 
have some parallels with the evolution of the F15/LAM4/KZN strain. Similarly, the MDR 
F28 strain has the potential to acquire resistance to additional drugs to become XDR in the 
future. The vast majority of XDR isolates belongs to the F15/LAM4/KZN family; IS6110 
RFLP patterns suggest clonal spread with evolving genotypes. Spoligotyping alone cannot 
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be used for epidemiological purposes. Different SITs have also been found in isolates 
belonging to the same IS6110 RFLP family.  
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DNA Extraction Solutions 
 
1.1 10x TE Buffer 
Trizma base (Sigma-Aldrich, USA)    1.21g 
EDTA (Sigma-Aldrich, USA)            0.37g 
 
Weigh out the required amounts of reagent powders and dissolve the trizma base in 80ml 
of distilled water, pH to 8 using concentrated HCl (Merck).  Add the EDTA and dissolve. 
Check the final pH and adjust to a final volume of 100ml. Autoclave at 121°C for 15 
minutes. 
 
1x TE Buffer 
Dilute 10ml of 10x TE Buffer into 90ml of triple distilled water. Store at room 
temperature. 
 
1.2 Lysozyme (10mg/ml) (Sigma-Aldrich, USA) 
Add 1ml of distilled water to 10mg of lysozyme powder. Store at 4°C until 
 
1.3 Proteinase K (10mg/ml) (Roche Diagnostics) 
Add 10ml of distilled water to 100mg of proteinase K powder. Store at 4°C until.   
 
1.4 10% Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich, USA) 




1.5 5M Sodium Chloride (NaCl) (Sigma-Aldrich, USA) 
Weigh 14.6 g of NaCl powder and dissolve in 50ml of distilled water, autoclave at 121°C 
for 15 minutes. 
 
1.6 CTAB-NaCl Solution 
NaCl (Sigma-Aldrich, USA)               4.1g 
CTAB (Sigma-Aldrich, USA)            10g 
 
Weigh out the required amounts of reagent powders and dissolve in 100ml of distilled 
water, the solution is heated to 65°C until powders are completely dissolved. 
 
1.7 Chloroform: Isoamyl alcohol (24:1) 
Add 1ml of isoamyl alcohol (Sigma-Aldrich, USA) to 24ml of chloroform (Sigma-Aldrich, 
USA). 
 
1.8 70% ethanol 











1.9 1% agarose gel (140ml) 
Agarose powder (Lonza, USA)                      1.4g 
1x TBE buffer                                                140ml 
Ethidium bromide                                          140µl 
 
The agarose powder was weighed and added to a flask containing 1x TBE buffer.  The 
mixture was boiled using a microwave until the powder dissolved.  It was allowed to cool 
and ethidium bromide was added. 
 
1.10 10xTBE Buffer 
Trizma base (Sigma-Aldrich, USA)    108g 
Boric acid (Sigma-Aldrich, USA)       55g 
EDTA (Sigma-Aldrich, USA)             9.3g 
 
Weigh out the required amounts of the reagents and dissolve in 1000ml of distilled water. 
 
1x TBE 
Add 100ml of 10x TBE to 900ml of distilled water. 
 
1.11 Ethidium Bromide (5µg/ml) 
Weigh out 10mg of ethidium bromide powder and dissolve in 20ml of distilled water. 






1.12 Sample loading dye 
1% Double dye  
Bromphenol Blue (Sigma-Aldrich, USA)   1g  
 Xylene cyanole (Sigma-Aldrich, USA)      1g 
 
Weigh out the required amounts of reagent powders and dissolve in 100ml of distilled 
water. 
 
50 ml of Loading Dye from 1% Double Dye (DD) stock: 
10x TBE                                5 ml 
Glycerol (Merck, SA)         25 ml 
1% Double dye                    5 ml 
 

















2a 20x SSPE Solution 
0.2M Na2HPO4.2H2O (Sigma-Aldrich, USA)             35.6g 
3.6M NaCl (Sigma-Aldrich, USA)                           210.24g 
20mM EDTA (Sigma-Aldrich, USA)                             7.4g 
 
Weigh out the required amounts of the reagents and dissolve in 800ml of distilled water 
using a magnetic stirrer, adjust pH to 7.4 using 4M NaOH. Add distilled water to get a 
final volume of 1000ml.  
 
2b 0.5M EDTA 
Dissolve 93.05g of EDTA (Sigma-Aldrich, USA) powder in 450ml of distilled water, 
adjust pH to 8 using NaOH pellets (Sigma-Aldrich, USA).  Add distilled water to get a 
final volume of 500ml. 
 
2c 10% SDS solution 
Weigh 10g of SDS powder (Sigma-Aldrich, USA) and dissolve in 100ml of distilled water. 
 
2.1 2x SSPE 0.1% SDS 
Add 26ml of 20x SSPE and 2.6ml of 10% SDS to 231.4ml of distilled water. 
 
2.2 2x SSPE 0.5% SDS 
Add 102ml of 20x SSPE and 51ml of 10% SDS to 867ml of distilled water. 
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2.3 2x SSPE 
Add 50ml of 20x SSPE to 450ml of distilled water. 
 
2.4 1% SDS 
Add 40ml of 10% SDS to 360ml of distilled water. 
 
2.5 20mM EDTA 





















 IS6110 RFLP Solutions 
 
3a 20x SSC Solution 
3M NaCl (Sigma-Aldrich, USA)                                             175g   
0.3M Tri-sodium citratedihydrate (Merck, SA)                        88g 
 
Weigh out the required amounts of the reagents and dissolve in 800ml of distilled water, 
pH to 7.0 using concentrated HCl (Merck, SA) and adjust to a final volume of 1000ml. 
 
3.1 10x SSC Solution 
Add 500ml of 20x SSC to 500ml of distilled water. 
 
3.2 1:100 HCl 
Dissolve 5ml of concentrated HCl (Merck, SA) in 495ml of distilled water. 
 
3.3 Soak I Solution 
0.5M NaOH pellets (Sigma-Aldrich, USA)        20g 
1.5M NaCl (Sigma-Aldrich, USA)                87.66g 
 







3.4 Soak II Solution 
0.5M Trizma base (Sigma-Aldrich, USA)     62.6g 
1.5M NaCl (Sigma-Aldrich, USA)              87.67g 
Conc. HCl (Merck, SA)                                   40ml 
 
Weigh out the required amounts and volume of the reagents and dissolve in 800ml of 
distilled water, pH to 7.2 using concentrated HCl (Merck, SA) and adjust to a final volume 
of 1000ml. 
 
3.5 Hybridisation buffer 
Hybridisation buffer (Amersham, UK)                 270ml   
5M NaCl (Sigma-Aldrich, USA)                            30ml   
Blocking agent (Amersham, UK)                           15g 
 
Weigh out the required amount and volumes of reagents.  Dissolve NaCl in hybridisation 
buffer using a stirrer bar on a magnetic stirrer, add small amounts of blocking agent slowly 
and heat solution at 60°C to enable blocking agent to dissolve. Buffer is aliquoted into 










3.6 Primary wash buffer 
Urea (Sigma-Aldrich, USA)                           360g   
20xSSC                                                            25mL   
SDS (Sigma-Aldrich, USA)                              4g 
 
Weigh out the required amounts and volume of the reagents and dissolve in 800ml of 
distilled water using a magnetic stirrer bar, adjust to a final volume of 1000ml. 
 
3.7 2x SSC Solution 



















Additional spoligotype patterns obtained in this study. 
 
1. Spoligotype patterns obtained among the susceptible isolates. 
43 Oligonucleotides 





2. Additional spoligotype patterns among MDR and XDR TB isolates. 
43 Oligonucleotides 
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IS6110 RFLP patterns 
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IS6110 RFLP patterns (2005-2006) 
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2 & 10: Beijing family patterns 
Lane 3: F28 family pattern 
Lane 5: unique pattern 
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IS6110 RFLP patterns (2008-2009)  
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2-4, 6, 8, 10-11, 13-18, 20: F15/LAM4/KZN family patterns 
Lane 5, 7, 12: F28 family patterns 
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IS6110 RFLP patterns (2005-2006) 
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
Lane 2, 6, 8, 11: F28 family patterns 
Lane 3, 5, 7, 9, 12, 18: F15/LAM4/KZN family patterns 
Lane 4, 10, 13, 14, 16, 17, 20: unique patterns 
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IS6110 RFLP patterns (2005-2006) 
Lane 1& 17: Jack‘s standard molecular weight marker (0.7-15 kbps)  
Lane 2-3, 5-6, 8-13, 15: F15/LAM4/KZN family patterns 
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IS6110 RFLP patterns for (2005-2006) and (2008-2009)  
Lane 1 & 19: Jack‘s standard molecular weight marker (0.7-15 kbps) 
(2005-2006): lane 2-3 F15/LAM4/KZN family patterns 
Lane 4: F28 family patterns,  
Lane 5-7: unique patterns 
(2008-2009): 
Lane 8-18, 19: unique patterns  
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